Singer can easily spike this generics' assertion too (if and only if we get a fair panel).
Generics are referencing a court case where they defeat another drug from Nuvo for lack of written description. Nuvo's patents are vague in terms of API amount: "enough to be effective".
Amarin's patents are specific, quantifying API amounts.
Lawyers please chime in, I'm always the layman, but I'm not aware of efficacy data being a universal or even a standard requirement for drug patents.
News 
Market Data 
Discover 
